Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1921 + adebrelimab + SHR-8068
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SHR-A1921 + adebrelimab + SHR-8068 is an investigational **combination therapy** comprising three distinct agents, developed for the treatment of advanced solid tumors. - **SHR-A1921** is an experimental drug investigated in combination studies for solid tumors and other cancers. Modality and mechanism of action specific to SHR-A1921 are not yet publicly disclosed, but clinical trials indicate evaluation as part of anti-cancer therapies[1][3][5][7]. - **Adebrelimab** (also known as SHR-1316) is a fully-humanized IgG4 monoclonal antibody targeting programmed cell death ligand 1 (**PD-L1**), functioning as a **PD-L1 inhibitor** to block immune checkpoint signaling, activate T-cells, and augment anti-tumor immune responses[2]. - **SHR-8068** is also an experimental drug included in clinical studies with SHR-A1921 and adebrelimab[3]. Publicly available details about its mechanism and target are currently unavailable. This combination is in **early-stage clinical trials** for the treatment of **advanced solid tumors** and potentially other malignancies[3].
- Other names
- SHR-A1921 + adebrelimab + SHR-8068
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on SHR-A1921 + adebrelimab + SHR-8068.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1921 + adebrelimab + SHR-8068.